JP2022520978A5 - - Google Patents

Info

Publication number
JP2022520978A5
JP2022520978A5 JP2021548221A JP2021548221A JP2022520978A5 JP 2022520978 A5 JP2022520978 A5 JP 2022520978A5 JP 2021548221 A JP2021548221 A JP 2021548221A JP 2021548221 A JP2021548221 A JP 2021548221A JP 2022520978 A5 JP2022520978 A5 JP 2022520978A5
Authority
JP
Japan
Prior art keywords
cells
amino acid
polypeptide according
domain
tumor cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021548221A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022520978A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/018680 external-priority patent/WO2020172189A1/en
Publication of JP2022520978A publication Critical patent/JP2022520978A/ja
Publication of JP2022520978A5 publication Critical patent/JP2022520978A5/ja
Pending legal-status Critical Current

Links

JP2021548221A 2019-02-18 2020-02-18 オルソポックスウイルス主要組織適合性複合体（ｍｈｃ）クラスｉ様タンパク質（ｏｍｃｐ）と腫瘍特異的結合パートナーを用いた二重特異性融合タンパク質 Pending JP2022520978A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962807190P 2019-02-18 2019-02-18
US62/807,190 2019-02-18
PCT/US2020/018680 WO2020172189A1 (en) 2019-02-18 2020-02-18 BISPECIFIC FUSION PROTEIN USING ORTHOPOXVIRUS MAJOR HISTOCOMPATIBILITY COMPLEX (MHC) CLASS l-LIKE PROTEIN (OMCP) AND TUMOR-SPECIFIC BINDING PARTNER

Publications (2)

Publication Number Publication Date
JP2022520978A JP2022520978A (ja) 2022-04-04
JP2022520978A5 true JP2022520978A5 (https=) 2023-02-09

Family

ID=72144178

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021548221A Pending JP2022520978A (ja) 2019-02-18 2020-02-18 オルソポックスウイルス主要組織適合性複合体（ｍｈｃ）クラスｉ様タンパク質（ｏｍｃｐ）と腫瘍特異的結合パートナーを用いた二重特異性融合タンパク質

Country Status (11)

Country Link
US (2) US20230002450A1 (https=)
EP (1) EP3927722A4 (https=)
JP (1) JP2022520978A (https=)
KR (1) KR20210131373A (https=)
CN (1) CN114072416A (https=)
AU (1) AU2020226493B2 (https=)
CA (1) CA3130582A1 (https=)
GB (1) GB2596001B (https=)
IL (1) IL285668A (https=)
SG (1) SG11202108878VA (https=)
WO (1) WO2020172189A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108261426B (zh) * 2017-01-04 2019-04-05 杭州康万达医药科技有限公司 药物组合物及其在治疗肿瘤和/或癌症的药物中的应用
AU2018219887B2 (en) 2017-02-08 2024-08-15 Dragonfly Therapeutics, LLC Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
BR112020015994A2 (pt) 2018-02-08 2020-12-15 Dragonfly Therapeutics, Inc. Terapia de combinação do câncer que envolve proteínas de ligação multiespecíficas que ativam células natural killer
CA3237846A1 (en) 2018-02-08 2019-08-15 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the nkg2d receptor
WO2019164930A1 (en) 2018-02-20 2019-08-29 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use
KR20210018275A (ko) * 2018-05-07 2021-02-17 드래곤플라이 쎄라퓨틱스, 인크. Nkg2d, cd16 및 종양-연관 항원에 결합하는 단백질
KR102835308B1 (ko) 2018-08-08 2025-07-21 드래곤플라이 쎄라퓨틱스, 인크. Nkg2d, cd16 및 종양 관련 항원에 결합하는 단백질
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
EP3833392A4 (en) 2018-08-08 2022-05-18 Dragonfly Therapeutics, Inc. MULTISPECIFIC BINDING PROTEINS FOR BINDING CD33, NKG2D AND CD16 AND METHODS OF USE
JP7512394B2 (ja) 2020-05-06 2024-07-08 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｎｋｇ２ｄ、ｃｄ１６及びｃｌｅｃ１２ａに結合するタンパク質
EP4301774A4 (en) 2021-03-03 2025-08-13 Dragonfly Therapeutics Inc METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN
WO2022258691A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040038339A1 (en) * 2000-03-24 2004-02-26 Peter Kufer Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex
US20110123440A1 (en) * 2005-03-29 2011-05-26 Genevieve Hansen Altered Antibody FC Regions and Uses Thereof
WO2007002905A1 (en) * 2005-06-29 2007-01-04 University Of Miami Antibody-immune cell ligand fusion protein for cancer therapy
WO2011085178A1 (en) * 2010-01-11 2011-07-14 Trustees Of Dartmouth College Monomeric bi-specific fusion protein
CA2963274C (en) * 2014-12-05 2024-01-30 Avidbiotics Corp. Insertable variable fragments of antibodies and modified a1-a2 domains of nkg2d ligands
EP3233192B1 (en) * 2014-12-15 2021-04-14 Washington University Compositions and methods for targeted cytokine delivery
WO2016134371A2 (en) * 2015-02-20 2016-08-25 Ohio State Innovation Foundation Bivalent antibody directed against nkg2d and tumor associated antigens
WO2016166139A1 (en) * 2015-04-14 2016-10-20 Eberhard Karls Universität Tübingen Bispecific fusion proteins for enhancing immune responses of lymphocytes against tumor cells
FR3035879B1 (fr) * 2015-05-07 2025-02-28 Lab Francais Du Fractionnement Mutants fc a activite fonctionnelle modifiee
HRP20240997T1 (hr) * 2015-08-04 2024-10-25 Xyphos Biosciences Inc. Varijabilni fragmenti antitijela koji se mogu umetnuti i modificirane α1-α2 domene nkg2d liganada, kao i neprirodni nkg2d ligandi koji se vežu za neprirodne nkg2d receptore
CN106467576B (zh) * 2015-08-18 2020-04-07 中国科学院微生物研究所 一种抗体融合蛋白及其制备方法与应用
AU2017213659B2 (en) * 2016-02-05 2024-04-18 Washington University Compositions and methods for targeted cytokine delivery
CN109310766A (zh) * 2016-02-26 2019-02-05 伊蒙纽斯私人有限公司 多特异性分子
JP2019523016A (ja) * 2016-06-24 2019-08-22 サイフォス、バイオサイエンシズ、インコーポレイテッドＸｙｐｈｏｓ Ｂｉｏｓｃｉｅｎｃｅｓ Ｉｎｃ． 抗体の挿入可能な可変フラグメントおよびｎｋｇ２ｄリガンドの改変型ａ１−ａ２ドメイン
AU2018219887B2 (en) * 2017-02-08 2024-08-15 Dragonfly Therapeutics, LLC Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
CN107226866A (zh) * 2017-07-05 2017-10-03 中国药科大学 一种抗cd24人源化抗体融合蛋白

Similar Documents

Publication Publication Date Title
JP2022520978A5 (https=)
GB2596001A (en) Bispecific fusion protein using orthopoxvirus major histocompatibility complex (MHC) class 1-like protein (OMCP) and tumor-specific binding partner
JP2024099850A5 (https=)
Yan et al. Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment
JP2020506971A5 (https=)
JP7457899B2 (ja) 修飾された免疫細胞及びその使用
Rizeq et al. Towards understanding the mechanisms of actions of carcinoembryonic antigen‐related cell adhesion molecule 6 in cancer progression
Junnila et al. Genome-wide gene copy number and expression analysis of primary gastric tumors and gastric cancer cell lines
WO2023020423A1 (en) Ror1 car or ror1 /cd19 dual car t cells for the treatment of tumors
JP2022527635A5 (https=)
JP2021525731A5 (https=)
JP2021530243A5 (https=)
FI3579848T3 (fi) Monispesifisiä sitovia proteiineja luonnollisten tappajasolujen aktivointiin ja niiden terapeuttisia käyttöjä syövän hoitoon
JP2022514420A5 (https=)
JP2019531728A5 (https=)
JP2021512614A5 (https=)
JP2020522474A5 (https=)
JP2019522054A5 (https=)
JP2025124799A (ja) 細胞内部移行をモジュレートするための組成物および方法
JP2020521448A5 (https=)
JP2016531583A5 (https=)
Peng et al. The CEA/CD3-bispecific antibody MEDI-565 (MT111) binds a nonlinear epitope in the full-length but not a short splice variant of CEA
WO2013123861A1 (zh) 一种能与egfr、her2、vegf高效结合的融合蛋白、其编码序列及用途
Chu et al. Versatile CAR T-cells for cancer immunotherapy
Haist et al. Engineering a single-chain variable fragment of cetuximab for CAR T-cell therapy against head and neck squamous cell carcinomas